[go: up one dir, main page]

ATE244015T1 - Formulierungen fuer faktor ix - Google Patents

Formulierungen fuer faktor ix

Info

Publication number
ATE244015T1
ATE244015T1 AT95915040T AT95915040T ATE244015T1 AT E244015 T1 ATE244015 T1 AT E244015T1 AT 95915040 T AT95915040 T AT 95915040T AT 95915040 T AT95915040 T AT 95915040T AT E244015 T1 ATE244015 T1 AT E244015T1
Authority
AT
Austria
Prior art keywords
factor
formulations
administration
methods
storage
Prior art date
Application number
AT95915040T
Other languages
English (en)
Inventor
Lawrence Bush
Chandra Webb
Original Assignee
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Genetics Llc filed Critical Inst Genetics Llc
Application granted granted Critical
Publication of ATE244015T1 publication Critical patent/ATE244015T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95915040T 1994-04-26 1995-04-06 Formulierungen fuer faktor ix ATE244015T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/233,663 US6372716B1 (en) 1994-04-26 1994-04-26 Formulations for factor IX
PCT/US1995/004263 WO1995028954A1 (en) 1994-04-26 1995-04-06 Formulations for factor ix

Publications (1)

Publication Number Publication Date
ATE244015T1 true ATE244015T1 (de) 2003-07-15

Family

ID=22878181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95915040T ATE244015T1 (de) 1994-04-26 1995-04-06 Formulierungen fuer faktor ix

Country Status (11)

Country Link
US (1) US6372716B1 (de)
EP (1) EP0758248B1 (de)
JP (4) JPH09512267A (de)
AT (1) ATE244015T1 (de)
AU (1) AU695084B2 (de)
CA (1) CA2182200C (de)
DE (1) DE69531204T2 (de)
DK (1) DK0758248T3 (de)
ES (1) ES2202356T3 (de)
PT (1) PT758248E (de)
WO (1) WO1995028954A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
JP5090605B2 (ja) 2000-05-03 2012-12-05 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 凝固因子ｖｉｉの皮下投与
RU2163140C1 (ru) * 2000-07-05 2001-02-20 Гематологический научный центр РАМН Концентрат фактора ix системы свертывания крови и способ его получения
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP2283856B1 (de) 2002-06-21 2017-09-20 Novo Nordisk Health Care AG Stabiliserte feste Zusammensetzungen von Faktor VIIa Polypeptiden
HRP20050670A2 (en) * 2003-02-01 2005-12-31 WYETH Neuralab Limited Active immunization to generate antibodies to soluble a-beta
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1628677B1 (de) 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Stabilisierung von proteinen in lösung
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
BRPI0413518A (pt) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
KR20140093711A (ko) 2003-12-19 2014-07-28 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
JP2008505119A (ja) * 2004-06-30 2008-02-21 ネクター セラピューティクス アラバマ，コーポレイション 高分子−第ｉｘ因子部分の抱合体
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
AR052051A1 (es) * 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
WO2006066171A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid βετα antibodies for use in improving cognition
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
TW200638943A (en) * 2005-01-28 2006-11-16 Wyeth Corp Stabilized liquid polypeptide formulations
ES2439709T3 (es) 2005-06-21 2014-01-24 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a la IL-1beta
AU2006308921C1 (en) 2005-11-01 2013-01-24 Wyeth Llc Sodium chloride solution for drug reconstitution or dilution
CA2630115A1 (en) * 2005-11-22 2007-05-31 Wyeth Immunoglobulin fusion protein formulations
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2094306A2 (de) 2006-12-20 2009-09-02 XOMA Technology Ltd. Behandlung von il-1-beta-bedingten erkrankungen
MX2009011127A (es) * 2007-04-18 2010-03-10 Janssen Alzheimer Immunotherap Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CA2687246A1 (en) * 2007-06-01 2008-12-11 Acologix, Inc. High temperature stable peptide formulation
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5536666B2 (ja) 2007-12-20 2014-07-02 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 痛風の治療のための方法
WO2009082648A1 (en) * 2007-12-21 2009-07-02 Inspiration Biopharmaceuticals, Inc. Stabilized factor ix formulations containing trehalose
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX2011006347A (es) * 2008-12-16 2011-09-06 Genzyme Corp Conjugados de oligosacaridos-proteinas.
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
JP5828909B2 (ja) 2011-01-10 2015-12-09 シーティー アトランティック リミテッド 腫瘍関連抗原結合抗体を含む併用療法
US20140093514A1 (en) 2011-06-03 2014-04-03 University Of Zurich Magea3 binding antibodies
US20140186363A1 (en) 2011-06-03 2014-07-03 University Of Zurich Magea3 binding antibodies
EP3050900A1 (de) 2011-12-19 2016-08-03 Xoma (Us) Llc Verfahren zur behandlung von akne
JP2015509091A (ja) 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
WO2014052490A1 (en) 2012-09-25 2014-04-03 Biogen Idec Ma Inc. Methods of using fix polypeptides
CA2890848C (en) 2012-11-09 2020-11-17 Puget Sound Blood Center Protein stabilizing factors apolipoprotein a-1 or high density lipoprotein
CA2904586A1 (en) 2013-03-08 2014-09-12 The Curators Of The University Of Missouri Methods and compositions for the treatment and/or prevention of type 1 diabetes
EP2968498A4 (de) 2013-03-15 2016-09-07 Biogen Ma Inc Faktor-ix-polypeptidformulierungen
EP3019533B1 (de) 2013-07-11 2020-01-08 The Scripps Research Institute Doppelwendel-immunglobulinfusionsproteine und zusammensetzungen daraus
EP3022224A2 (de) 2013-07-18 2016-05-25 Fabrus, Inc. Antikörper mit ultralangen komplementaritätsbestimmenden regionen
AU2014290361B2 (en) 2013-07-18 2019-04-18 Taurus Biosciences, Llc Humanized antibodies with ultralong complementarity determining regions
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US9913818B2 (en) 2013-10-09 2018-03-13 Nestec S.A. Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome
WO2015057834A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Peptidic chimeric antigen receptor t cell switches and uses thereof
JP6637415B2 (ja) 2013-10-15 2020-01-29 ザ スクリプス リサーチ インスティテュート キメラ抗原受容体ｔ細胞スイッチおよびその使用
JP6572497B2 (ja) 2013-12-18 2019-09-11 ザ・スクリップス・リサーチ・インスティテュート 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
SG10201913735SA (en) 2014-03-24 2020-03-30 Bioverativ Therapeutics Inc Lyophilized factor ix formulations
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
EP3283113A4 (de) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimierte pne-basierte chimäre t-zell-rezeptor-schalter und verwendungen davon
JP2018517711A (ja) 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー 細胞表面タンパク質に対する抗体を作製する方法
NZ737851A (en) 2015-06-01 2019-08-30 Medigene Immunotherapies Gmbh T-cell receptor specific antibodies
WO2016193299A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T cell receptor library
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
UA124616C2 (uk) 2015-07-06 2021-10-20 Юсб Біофарма Срл Зв'язуюче тау-білок антитіло
CN108348581B (zh) 2015-09-04 2022-07-01 斯克利普斯研究所 胰岛素免疫球蛋白融合蛋白
EP3387019B1 (de) 2015-12-09 2021-10-20 The Scripps Research Institute Relaxin-immunglobulin-fusionsproteine und verfahren zur verwendung
BR112018012826A2 (pt) 2015-12-23 2018-12-04 Medigene Immunotherapies Gmbh método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1
ES3030503T3 (en) 2016-10-19 2025-06-30 Scripps Research Inst Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
CA3158893A1 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
WO2022257979A1 (en) 2021-06-09 2022-12-15 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
US20250108109A1 (en) 2021-12-01 2025-04-03 UCB Biopharma SRL Formulations comprising fab-peg
CN118354793A (zh) 2022-04-29 2024-07-16 普瑞诺生物科技公司 用于治疗嗜酸性粒细胞驱动的疾病和病症的方法和组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5480406A (en) * 1977-12-09 1979-06-27 Tanabe Seiyaku Co Ltd Preparation of urokinase for injection
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
AT376881B (de) * 1983-05-02 1985-01-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4952675A (en) * 1985-02-01 1990-08-28 New York University Method for purifying antihemophilic factor
ATE74164T1 (de) 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
ES2045167T5 (es) 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
CA2078721A1 (en) * 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
JPH05331071A (ja) * 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX

Also Published As

Publication number Publication date
CA2182200C (en) 1999-02-02
JP2010077148A (ja) 2010-04-08
CA2182200A1 (en) 1995-11-02
ES2202356T3 (es) 2004-04-01
JP2006219500A (ja) 2006-08-24
AU2207595A (en) 1995-11-16
JP2007224052A (ja) 2007-09-06
DE69531204D1 (de) 2003-08-07
AU695084B2 (en) 1998-08-06
JPH09512267A (ja) 1997-12-09
DK0758248T3 (da) 2003-10-27
WO1995028954A1 (en) 1995-11-02
JP4789698B2 (ja) 2011-10-12
DE69531204T2 (de) 2004-04-22
US6372716B1 (en) 2002-04-16
PT758248E (pt) 2003-11-28
EP0758248B1 (de) 2003-07-02
EP0758248A1 (de) 1997-02-19

Similar Documents

Publication Publication Date Title
DE69531204D1 (de) Formulierungen fuer faktor ix
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
ATE216590T1 (de) Arzneimittelformulierungen für il-12
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
WO2001005355A3 (en) Formulations for il-11
IL140710A0 (en) Pulmonary delivery of active agents
DE69524742D1 (de) Interleukin-11 präparat
ES2132253T3 (es) Lipidos cationicos.
ES2170102T3 (es) Aminociclohexilesteres y utilizacion de los mismos.
TR199901077A2 (en) �spen�iyari form�lasyonlar.
LU90366I2 (fr) Nasonex
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
SE9201628D0 (sv) Pharmaceutical composition
EP0895777A3 (de) Zusammensetzungen auf Basis von Persäuren
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
BG100248A (bg) Инхибитори на скваленсинтетаза
DE69330601D1 (de) Serotoninergische ergolin derivate
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
DE69431662D1 (de) Stabilisierte tablettenformulierung
BG104452A (en) New derivatives of the methylenebisphosphonic acid
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0758248

Country of ref document: EP